Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics aimed at treating cancer. The company operates in the biopharmaceutical market, focusing on innovative solutions that transform scientific insights into effective medical treatments. Genmab serves a global client base, including healthcare providers, research institutions, and pharmaceutical companies. The business model revolves around the research, development, and commercialization of proprietary antibody technologies, which are designed to target and destroy cancer cells. Revenue is generated through product sales, licensing agreements, and strategic partnerships with other biotech and pharmaceutical companies. Genmab's shares are publicly traded on the Nasdaq Copenhagen and the Nasdaq Global Select Market in the United States under the ticker symbol GMAB.

Keywords: antibody therapeutics, cancer treatment, biotechnology, biopharmaceutical, innovation, research, development, commercialization, Nasdaq, partnerships.